Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aoxing Pharmaceutical, a specialty pharmaceutical company focusing on manufacturing, research, development and distribution of narcotic and pain-management products, has reported sales of $1.74m for the first quarter ended 30 September 2010, an increase of 20%, compared to $1.45m for the comparable period in 2009.
Subscribe to our email newsletter
Aoxing Pharma has posted a net loss of $653,939 for the first quarter 2010, or $0.01 loss per diluted share, compared to $2.29m, or $0.05 loss per diluted share, for the comparable period in 2009.
China Aoxing chairman and CEO Zhenjiang Yue said that following the recent completion of the facility for the joint venture with Johnson Matthey and with full GMP certification expected by year-end and with the expected GMP re-certification of pill formulation production, they were poised for a very successful 2011.
"We continue to be pleased with our quarterly results, as our financial condition remains strong," Yue said.
"We look forward to re-launching our recertified products, launching new products and begin manufacturing API for the China markets in the calendar year 2011."